GlassScriptPhysician profile
Ramesh M Patel
NPI 1174503924
$5,239.55
in general payments reported to CMS, 2019-2025
47 companies · $1,474 in 2025
The $1,474 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,186 · 2020: $289 · 2021: $154 · 2022: $461 · 2023: $581 · 2024: $1,095 · 2025: $1,474.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,149.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $872.66 | 2021-2025 | Ozempic, Rybelsus |
| Amgen INC. | $660.05 | 2019-2025 | Repatha, Repatha, Prolia |
| Pfizer INC. | $446.54 | 2019-2025 | |
| Glaxosmithkline, LLC. | $391.20 | 2019-2025 | Trelegy Ellipta |
| Intuitive Surgical, INC. | $378.34 | 2025 | |
| Eisai INC. | $253.58 | 2024-2025 | |
| Lilly USA, LLC | $241.57 | 2023-2025 | Kisunla, Mounjaro, Zepbound |
| Abbvie INC. | $163.23 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $137.41 | 2019-2025 | Jardiance |
| Allergan, INC. | $134.35 | 2019 | |
| Amarin Pharma, INC. | $128.13 | 2020-2023 | |
| Janssen Pharmaceuticals, INC | $118.94 | 2019 | |
| Scilex Pharmaceuticals INC. | $118.65 | 2023-2024 | Ztlido |
| Dermira, INC. | $108.31 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $104.90 | 2019-2024 | Farxiga |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramesh Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.